Literature DB >> 1869095

Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter.

P J Eifel1, T W Burke, L Delclos, J T Wharton, M J Oswald.   

Abstract

Between 1965 and 1985, 160 patients had initial treatment at the M. D. Anderson Cancer Center for Stage I adenocarcinoma of the uterine cervix less than or equal to 4 cm in diameter. Of these patients, 84 were treated with radiation therapy (RT) alone, 20 were treated with external and intracavitary radiation followed by total hysterectomy (R + S), and 56 were treated with radical hysterectomy (RH). Survival rate was strongly correlated with tumor volume (P = 0.0008), lymphangiogram findings (P = 0.01), and tumor grade (P = 0.0018). Patients with a normal-appearing cervix or a small visible or palpable tumor that did not expand the cervix more than 3 cm had survival and pelvic-control rates of more than 90% after treatment with RH or RT. However, after 5 years, 45% of patients treated with RH for tumors 3-4 cm in diameter had disease recurrence in the pelvis, compared with 11% of patients treated with either RT or R + S (P = 0.025). For patients treated with RH, recurrence was also strongly correlated with findings of lymph/vascular space invasion (P = 0.0004) and poorly differentiated tumor (P = 0.018). Major complication rates were comparable for the three treatment groups. The high rate of pelvic recurrence following treatment with radical hysterectomy alone for patients with tumors greater than 3 cm in diameter, particularly in the presence of lymph/vascular space invasion, poorly differentiated features, and/or positive nodes, should be considered in planning the primary management of patients with Stage I adenocarcinoma of the cervix.

Entities:  

Mesh:

Year:  1991        PMID: 1869095     DOI: 10.1016/0090-8258(91)90308-r

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

2.  A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.

Authors:  Caroline E Poorman; Cecilia G Ethun; Lauren M Postlewait; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solórzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2017-11-21       Impact factor: 5.344

3.  Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology.

Authors:  Joo-Young Kim; Byung Ho Nam; Jin-Ah Lee
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

Review 4.  Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.

Authors:  Astrid Baalbergen; Yerney Veenstra; Lukas Stalpers
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

5.  Effects of Treatment of Uterine Cervical Carcinoma Monitored by Magnetic Resonance Imaging - Sarajevo Experience.

Authors:  Amela Sofic; Azra Husic-Selimovic; Nermina Beslic; Azra Rasic; Dzenana Begic; Anja Tomic-Cica; Nejira Imsirevic
Journal:  Acta Inform Med       Date:  2017-03

6.  Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

Authors:  Bhavana Pothuri; Angeles Alvarez Secord; Deborah K Armstrong; John Chan; Amanda N Fader; Warner Huh; Joshua Kesterson; Joyce F Liu; Kathleen Moore; Shannon N Westin; R Wendel Naumann
Journal:  Gynecol Oncol       Date:  2020-04-23       Impact factor: 5.482

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.